Market Cap 411.32M
Revenue (ttm) 160.18M
Net Income (ttm) -69.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 57.75
Profit Margin -43.33%
Debt to Equity Ratio 1.15
Volume 3,176,200
Avg Vol 4,464,280
Day's Range N/A - N/A
Shares Out 265.37M
Stochastic %K 15%
Beta 0.62
Analysts Strong Sell
Price Target $5.40

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
aicdeftone
aicdeftone Nov. 23 at 5:55 AM
$AKBA Double Standard. That seems to be the common theme throughout most of the boards, especially here. How is it Bulls must prove their point through analysis, modeling, and facts while Bears do none of the above yet gladly accept accolades when the dice roll in their favor. I used to think weathermen had the easiest job.
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 23 at 3:12 AM
Hedge Alert Live - Protect Your Portfolio Contract: $AKBA $1.50 Put · DEC 19, 2025 Exp Entry Price: $0.07 - $0.30 Exit Price Target: $0.11 Profit Margin: +55% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
CustomCulture
CustomCulture Nov. 23 at 1:16 AM
$AKBA My modeling today on Akebia has uncovered some uncanny similarities related to the recent price movement. Respective to seemingly negative press release price drop; continued price decline has not fundamentally lined up. Thus, what would result in little to minimal price impact has cascaded down to an under valued PPS. Another poster has made mention of the R&R which at current is favored to reward. This chart is following the same patterns as the 4 below mentioned stocks prior to each respective M&A SGEN before PFE acquisition MDGL and VKTX before partnership rumors KRTX before buyout IMMU before GILD buyout 6 models today have yet to change my perception. GLTA
3 · Reply
DonnyDonowitz
DonnyDonowitz Nov. 23 at 1:13 AM
1 · Reply
jillychilly
jillychilly Nov. 23 at 12:02 AM
$AKBA Once you come on this board and make all kinds of high-flying prognostications for several quarters and they don`t come true you lose all your credibility. You people know who you are. You are batting one-thousand on Monday morning quarterbacking. The problem is that a lot of retail actually listens to you and invests money that MAYBE, they shouldn`t be, but they believe you and are chasing the golden goose. Then when you are criticized for it, tell people to STFU. If you are an attorney at all, you are probably an ambulance chaser. Endless pumping day in and day out is not needed.
7 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 22 at 9:51 PM
Enter: $AKBA Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.09 Profit : +87% (Turn every $1 into $1.87) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 9:03 PM
$AKBA $MVST After breaking through key resistance, the price launched a sharp offensive.
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 8:59 PM
$RGTI $AKBA Bullish sentiment is running high, driving the index steadily upward.
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 8:52 PM
$LKNCY $AKBA Bears are covering their shorts, further strengthening the upward trend.
0 · Reply
CustomCulture
CustomCulture Nov. 22 at 8:39 PM
$AKBA Short post today. One word for my remained state of optimism. “Accumulation“ GLTA
0 · Reply
Latest News on AKBA
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 10:21 AM EDT - 9 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript


Akebia Therapeutics Announces Multiple Positive Business Updates

Jan 13, 2025, 8:00 AM EST - 11 months ago

Akebia Therapeutics Announces Multiple Positive Business Updates


Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 20, 2024, 3:31 PM EST - 1 year ago

Q3 2024 Earnings: Hold Akebia Therapeutics


aicdeftone
aicdeftone Nov. 23 at 5:55 AM
$AKBA Double Standard. That seems to be the common theme throughout most of the boards, especially here. How is it Bulls must prove their point through analysis, modeling, and facts while Bears do none of the above yet gladly accept accolades when the dice roll in their favor. I used to think weathermen had the easiest job.
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 23 at 3:12 AM
Hedge Alert Live - Protect Your Portfolio Contract: $AKBA $1.50 Put · DEC 19, 2025 Exp Entry Price: $0.07 - $0.30 Exit Price Target: $0.11 Profit Margin: +55% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
CustomCulture
CustomCulture Nov. 23 at 1:16 AM
$AKBA My modeling today on Akebia has uncovered some uncanny similarities related to the recent price movement. Respective to seemingly negative press release price drop; continued price decline has not fundamentally lined up. Thus, what would result in little to minimal price impact has cascaded down to an under valued PPS. Another poster has made mention of the R&R which at current is favored to reward. This chart is following the same patterns as the 4 below mentioned stocks prior to each respective M&A SGEN before PFE acquisition MDGL and VKTX before partnership rumors KRTX before buyout IMMU before GILD buyout 6 models today have yet to change my perception. GLTA
3 · Reply
DonnyDonowitz
DonnyDonowitz Nov. 23 at 1:13 AM
1 · Reply
jillychilly
jillychilly Nov. 23 at 12:02 AM
$AKBA Once you come on this board and make all kinds of high-flying prognostications for several quarters and they don`t come true you lose all your credibility. You people know who you are. You are batting one-thousand on Monday morning quarterbacking. The problem is that a lot of retail actually listens to you and invests money that MAYBE, they shouldn`t be, but they believe you and are chasing the golden goose. Then when you are criticized for it, tell people to STFU. If you are an attorney at all, you are probably an ambulance chaser. Endless pumping day in and day out is not needed.
7 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 22 at 9:51 PM
Enter: $AKBA Calls Strike Price: $2 Expiry Date: DEC 19 2025 Buy in Price: $0.05 - $0.05 Sell Price: $0.09 Profit : +87% (Turn every $1 into $1.87) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 9:03 PM
$AKBA $MVST After breaking through key resistance, the price launched a sharp offensive.
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 8:59 PM
$RGTI $AKBA Bullish sentiment is running high, driving the index steadily upward.
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 8:52 PM
$LKNCY $AKBA Bears are covering their shorts, further strengthening the upward trend.
0 · Reply
CustomCulture
CustomCulture Nov. 22 at 8:39 PM
$AKBA Short post today. One word for my remained state of optimism. “Accumulation“ GLTA
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 8:08 PM
$AKBA $MVST Buyers have gained a crushing advantage.
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 8:04 PM
$RGTI $AKBA The bulls launched a general offensive, and the bears' defense line collapsed.
0 · Reply
JulianKomar
JulianKomar Nov. 22 at 7:57 PM
$LKNCY $AKBA The bearish consensus has been completely shattered.
0 · Reply
Mr_Pithy
Mr_Pithy Nov. 22 at 6:36 PM
$AKBA “An investor is a person who commits capital to secure a return on an investment.” MrPithy purchased 2,527,717 shares of AKBA with an expectation of a return. MrPithy has been up $8.9M and down $700K. MrPithy has averaged down on a number of occasions. MrPithy has not dumped or sold a single share. MrPithy has reviewed the detailed analyses by @Obviate and @hsainu who have both opined that AKBA has a forecasted price target 🎯 of $30.00. MrPithy concurs with the analyses. MrPithy is not listening to an investor whose handle is C Y I LOSE @cyilose. Good luck 🍀 to all of us.
6 · Reply
cyilose
cyilose Nov. 22 at 6:02 PM
$AKBA Pump and Dump A pump and dump is an illegal form of securities fraud where fraudsters artificially inflate the price of a stock (typically low-priced "penny stocks" or micro-cap cryptocurrencies) through false or misleading positive statements (the "pump"), and then sell their cheaply purchased shares at the inflated price (the "dump"). Once the perpetrators sell off their holdings, the price of the asset typically crashes, leaving other investors with significant losses. Folks, the next time a clown tells you this company will be trading at $30 next month, next quarter or next year know exactly who they really are.
1 · Reply
ROCKET123
ROCKET123 Nov. 22 at 4:45 PM
$AKBA The company seems to have failed miserably…we’re at $1.50 after a decade with 2 approved drugs, robust pipeline, international approvals and a large cash hoard…something just doesn’t add up…but you shouldn’t judge a book by its cover, right?…hmmm💎
1 · Reply
Pacomartinez
Pacomartinez Nov. 22 at 3:39 PM
$AKBA Am I the only person here who finds it odd that these companies (CSL Vifor and Medice) have amended agreements? I ask because no one seems to be talking about it. Why would these companies amend agreements that seem to benefit them less? That's like a professional athlete agreeing to amend his contract to receive less money. CSL Vifor agreed to return the rights to sell Vafseo to Fresenius. CSL Vifor has a partnership with Fresenius. So, why give back the rights to AKBA, which would result in Fresenius paying more to get Vafseo? Then there is Medice who has agreed to buy Vafseo from AKBA when it was costing them less to synthesize the drug themselves. There is more to these stories than meets the eye. I can't help but think that these amendments needed to be made as part of a BO. Something major is happening; if it is not a BO, I can see AKBA selling rights (for 100s of millions of dollars up front) for Vafseo in NDD. Did you know Medice has rights to NDD market as well? Comments
4 · Reply
joemist1
joemist1 Nov. 22 at 3:27 PM
$AKBA I am here to hold this for next 3 to 4 quarter. This has to bounce back!! I am buying at basement prices now compared to what this would be by next year end. You heard it right. Buying from retirement fund not for short term gains.
0 · Reply
Noname2022
Noname2022 Nov. 22 at 3:09 PM
$CRMD $AKBA $FMS $DVA https://www.chiefhealthcareexecutive.com/view/we-re-overdue-for-a-kidney-care-refresh-viewpoint
0 · Reply
DrKennethNoisewater
DrKennethNoisewater Nov. 22 at 2:36 PM
$AKBA very compelling R/R at these levels
3 · Reply
cyilose
cyilose Nov. 22 at 2:26 PM
$AKBA Fun fact: 30 is the total number of major and minor keys in Western tonal music.
1 · Reply
gaboriar
gaboriar Nov. 22 at 2:01 PM
$AKBA in May akebia estimated they had 12 months of inventory. That in a sense is guidance that is missing a metric to back into. I also can safely assume they thought they would avg more than 14M a qtr. so have they commented on how much inventory they have in the latest ER? My guess still 12 months…. Still bullish at this price.
1 · Reply